A former Theranos lab director testified on Friday in the Elizabeth Holmes federal fraud trial that the company was aware of the multiple concerns raised by physicians and Theranos employees prior to the Walgreens launch. The former lab director testified that he sent an email to Holmes in August 2013 that said that the blood-testing device was not ready for a launch in Walgreens stores. Surekha Gangakhedhar, like Rosendorff, testified that she also raised the concerns with Holmes and explained that the machines were not ready to be used on patients. An internal email presented to the jury alleged that Holmes requested that there be no mention of the tests being voided and that the incidents of healthcare providers asking about missing bicarbonate results should be chalked up to the test being unavailable for the samples collected.
Rosendorff reported the concerns to Holmes rather than former president and chief operating officer Sunny Balwani because he thought it would have more of an impact since Balwani frequently dismissed concerns, the scientist alleged. Holmes claimed her company would revolutionize blood testing with technology that could analyze tiny amounts of blood and inked retail partnerships with Walgreens and Safeway. The downward spiral culminated in the 2018 shutdown of the company, with the U.S. Securities and Exchange Commission accusing Holmes and Balwani of what it described as a "Massive fraud."
Holmes, along with Balwani, faces 10 counts of wire fraud and two counts of conspiracy to commit wire fraud over allegations that she knowingly misled investors by claiming Theranos technology could revolutionize blood testing.
source: https://www.massdevice.com/former-theranos-lab-director-takes-the-stand-says-elizabeth-holmes-was-nervous-amid-blood-test-inaccuracy-concerns/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.